Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:11/1/2009

PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Monday, November 2, 2009 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD.

To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast. The following abstracts are available on the AASLD website (AASLD.org).

PSI-7851

Late Breaker Abstract 17

"Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection" will be presented in a late breaker poster session on Monday November 2nd at 8am ET. Authors of the study are M. Rodriguez-Torres; E. Lawitz; S. Flach; J. M. Denning; E. Albanis; W. Symonds; M. M. Berrey.

RG7128/INFORM-1

Abstract 1585

"Combination Therapy with Nucleoside Polymerase R7128 and Protease R7227/ITMN-191 Inhibitors in Genotype 1 HCV Infected Patients: Interim Resistance Analysis of INFORM-1 Cohorts" will be presented in a poster session on Tuesday November 3rd at 8am ET. Authors of the study are A-D S. Le Pogam; M. Chhabra; S. Ali; J. Yan; M.J. Ilnicka; H. Kang; J.M. Wong; A. Kosaka; A. Ewing; A. Seshaadri; A. De La Rosa; W.Z. Bradford; K.Klumpp; N. Shulman; P.F. Smith; N. Cammack; I. Najera.

Abstract 193

"Combination Therapy With A Nucleoside Polymerase (R7128) And Protease (R7227/ITMN-191) Inhibitors In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1." will be presented at the Presidential Plenary session on Tuesday November 3rd at 8am ET. Authors of the study are E.J. Gane; S.K. Roberts; C.A. Stedman; P.W. Angus; B. Ritchie; R. Elston; D. Ipe; P.N. Morcos; I. Najera; T. Chu; M.M. Berrey; W.Z. Bradford; M. Laughlin; N. Shulman; P.F. Smith.

Abstract 1594

"Pharmacokinetics/Pharmacodynamics (PK/PD) of Combination R7227 and R7128 Therapy From INFORM-1 Demonstrates Similar Early HCV Viral Dynamics When R7227 is Combined With Either PEG-IFN/Ribavirin (SOC) or R7128" will be presented in a poster session on Tuesday November 3rd at 8am ET. Authors of the study are P.N. Morcos; R. Kulkarni; D. Ipe; S. Jumbe; J. Tran; W.Z. Bradford; W. Symonds; W.Z. Bradford; E.J. Gane; S.K. Roberts; N. Shulman; P.F. Smith.

PSI-938

Abstract 1605

"Novel 2 -F-2 -C-Methylpurine Nucleotide Analogs Are Active Inhibitors of HCV Replication And Lack Cross-Resistance with Other Nucleos(t)ide Analogs" will be presented in a poster session on Tuesday November 3rd at 8am ET. Authors of the study are A.M. Lam; C.L. Espiritu; H. Micolochick Steuer; E. Murakami; C. Niu; M. Keilman; D.N. Frick; J.A. Heck; M.J. Sofia; D. Nagarathnam; W. Chang; P.G. Reddy; B.S. Ross; B. Chun; P. Wang; H. Zhang; S. Rachakonda; D. Bao; M.J. Otto; P.A. Furman.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which has completed initial Phase 1 clinical studies, and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

www.pharmasset.com

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

SOURCE Pharmasset, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... New York , December 9, 2016 ... states that the top five players in the  Global ... 62.7% in the overall market in 2015. Players such ... Perkin Elmer have remained dominant in the global market ... efforts to ensure product innovation. Product upgrades and timely ...
(Date:12/8/2016)... 8, 2016  The Board of Directors of the ... Western Pennsylvania,s only pure life sciences investment ... with the succession plan developed by the Nominating and ... James (Jim) F. Jordan is selected to ... John W. Manzetti , who is elected to the ...
(Date:12/8/2016)... , December 8, 2016 AskLinkerReports.com ... comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market Research Report. ... application, and industry chain overview are all covered in the ... analysis, and investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):